Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s

• Main Authors: V. G. Bespalov, О. А. Belyaeva, G. S. Kireeva, K. Yu. Senchik, A. N. Stukov, A. M. Belyaev
• Format: Article
• Language: Russian
• Published: Tomsk National Research Medical Center of the Russian Academy of Sciences 2016-02-01
• Series: Sibirskij Onkologičeskij Žurnal
• Subjects: normo- and hyperthermic intraperitoneal chemoperfusion; ovarian cancer; dioxadet; cisplatin
• Online Access: https://www.siboncoj.ru/jour/article/view/25

Comparative study of antitumor activity of cisplatin and dioxadet in chemoperfusion treatment was carried out on ascitic ovarian cancer model in 172 Vistar female rats. Ovarian cancer was inoculated intraperitoneally at a volume of 0.5 ml per rat with concentration of tumor cells 2×107 / ml. The drugs were administered once in 48 hours after inoculation of ovarian cancer in maximum tolerated doses (MTD). Normothermic intraperitoneal chemoperfusion (IPEC) and hyperthermic intraperitoneal chemoperfusion (HIPEC) were performed with cisplatin or dioxadet at doses that were 5−20 times higher than those for their standard intraperitoneal administration. Antitumor effects of the drugs were estimated in increase of median survival time (MST). In case of IPEC and HIPEC cisplatin increased the MST by 317  % and 183  % (р<0.05) respectively, when dioxadet increased the MST by 244  % and 444  % (р<0.05) respectively compared to the control group of animals that didn’t receive any treatment. HIPEC with dioxadet is the most effective regimen in experimental treatment of advanced ovarian cancer.